A61P 19 - Drugs for skeletal disorders

Patents for A61P 19 - Drugs for skeletal disorders (81,981)
12/2001
12/05/2001	CN1324617A Medicine for treating hyperosteogeny and protrusion of lumber intervertebral disc
12/05/2001	CN1324614A Medicine for treating femoral head necrosis
12/05/2001	CN1075812C Prodrugs of morpholine tachykinin receptor antagonists
12/05/2001	CN1075809C Novel vitamin D analogues
12/05/2001	CN1075734C Medicine for treating hyperosteogeny
12/05/2001	CN1075730C Wind-dispelling meridian passage-dredging and pus-drawing out medicinal powder
12/04/2001	US6326507 Therapeutic compounds and methods of use
12/04/2001	US6326403 Cardiovascular disorders
12/04/2001	US6326398 Oxamic acids and derivatives as thyroid receptor ligands
12/04/2001	US6326388 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
12/04/2001	US6326385 Administering poltassium channel modulator
12/04/2001	US6326367 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
12/04/2001	US6326363 Methylenebisphosphonic acid derivatives
12/04/2001	US6326359 Adenosine A2A receptor agonists as antiinflammatory agents
11/2001
11/29/2001	WO2001090371A1 Mutated eukariotic translation initiation factor 2 alpha kinase 3, eif2ak3, in patients with neonatal insulin-dependent diabetes and multiple epiphyseal dysplasia (wolcott-rallison syndrome)
11/29/2001	WO2001090359A2 G-protein coupled receptors
11/29/2001	WO2001090334A2 Drug metabolizing enzymes
11/29/2001	WO2001090189A2 G-protein coupled receptor org3.
11/29/2001	WO2001090186A1 Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof
11/29/2001	WO2001090156A2 Card domain containing polypeptides, encoding nucleic acids, and methods of use
11/29/2001	WO2001090129A2 Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
11/29/2001	WO2001090104A2 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
11/29/2001	WO2001090103A2 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
11/29/2001	WO2001090101A1 Arylmethylamine derivatives for use as tryptase inhibitors
11/29/2001	WO2001090095A1 Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
11/29/2001	WO2001090094A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090093A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090092A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090091A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090090A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090086A1 A polymorph of 5-(4-aminosulfonyl-3-fluorophenyl)-4-cyclohexyl-2-methyloxazole
11/29/2001	WO2001090083A1 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
11/29/2001	WO2001090076A1 Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
11/29/2001	WO2001090074A2 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a)
11/29/2001	WO2001090070A2 Caspase inhibitors and uses thereof
11/29/2001	WO2001090069A1 Novel calcium receptor active molecules and method for preparing same
11/29/2001	WO2001090068A2 Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
11/29/2001	WO2001090063A2 Prodrug of an ice inhibitor
11/29/2001	WO2001090047A1 Novel mmp-2/mmp-9 inhibitors
11/29/2001	WO2001089593A1 Transfection system
11/29/2001	WO2001089570A2 Combination of growth hormone secretagogues and antidepressants
11/29/2001	WO2001089556A1 Inhibition of smad3 to prevent fibrosis and improve wound healing
11/29/2001	WO2001089552A1 Modulaton of alpha-6 integrin-mediated responses
11/29/2001	WO2001089536A2 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
11/29/2001	WO2001089521A1 Medicinal compositions containing thiophene derivatives
11/29/2001	WO2001089520A2 Dehydroascorbic acid formulations and uses thereof
11/29/2001	WO2001089494A2 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
11/29/2001	WO2001089451A2 Protease inhibitors
11/29/2001	WO2001089450A2 Treating musculoskeletal disorders using lp85 and analogs thereof
11/29/2001	WO2001070695A8 Pyridine derivatives as inhibitors of p38
11/29/2001	WO2001060835A8 Purine derivatives
11/29/2001	WO2001049305A3 Process for obtaining thylakoids from plants, pure thylakoids and use thereof
11/29/2001	WO2001042471A8 Polypeptides and polynucleotides encoding same
11/29/2001	WO2001038566A3 Screening method for candidate drugs
11/29/2001	WO2001038347A3 Peptides having antiangiogenic activity
11/29/2001	WO2001028567A3 Aminoalkylenephosphonates for treatment of bone disorders
11/29/2001	WO2000039114A3 Substituted oximes and hydrazones as neurokinin antagonists
11/29/2001	WO2000010548A3 19-nor-vitamin d3 compounds with calcemic activity
11/29/2001	US20010047105 EP4 receptor selective agonists in the treatment of osteoporosis
11/29/2001	US20010046993 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists
11/29/2001	US20010046963 Inhibiting cyclooxygenase-2 biosynthesis and Nuclear factor kappa B synthesis; treatment of arthritis and Alzheimer's disease; administering in food
11/29/2001	US20010046490 Cell surface molecule-induced macrophage activation
11/29/2001	EP1143949A3 19-nor-vitamin d3 compounds with calcemic activity
11/29/2001	DE10123349A1 New N-sulfonylated pipecolic acid derivatives, are matrix metalloprotease inhibitors useful e.g. for treating rheumatism, tumor progression, arteriosclerosis or inflammatory bowel disease
11/29/2001	CA2429199A1 Drug metabolizing enzymes
11/29/2001	CA2410987A1 Inhibition of smad3 to prevent fibrosis and improve wound healing
11/29/2001	CA2410593A1 Novel mmp-2/mmp-9 inhibitors
11/29/2001	CA2410520A1 Mutated eukariotic translation initiation factor 2 alpha kinase 3, eif2ak3, in patients with neonatal insulin-dependent diabetes and multiple epiphyseal dysplasia (wolcott-rallison syndrome)
11/29/2001	CA2410096A1 Card domain containing polypeptides, encoding nucleic acids, and methods of use
11/29/2001	CA2409868A1 Modulaton of alpha-6 integrin-mediated responses
11/29/2001	CA2409430A1 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
11/29/2001	CA2409367A1 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
11/29/2001	CA2408783A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	CA2408727A1 Benzophenones as inhibitors of il-1.beta. and tnf-.alpha.
11/29/2001	CA2408709A1 Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
11/29/2001	CA2408562A1 Dehydroascorbic acid formulations and uses thereof
11/29/2001	CA2408140A1 G-protein coupled receptors
11/29/2001	CA2408036A1 Combination of growth hormone secretagogues and antidepressants
11/29/2001	CA2407780A1 Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
11/29/2001	CA2406829A1 Protease inhibitors
11/29/2001	CA2380935A1 Caspase inhibitors and uses thereof
11/28/2001	EP1158050A1 Human cysteinyl leukotriene receptor (CysLT2)
11/28/2001	EP1158046A1 Superoxide Dismutase-4
11/28/2001	EP1158002A1 Human G-protein coupled receptor
11/28/2001	EP1157104A2 Pyk2 binding proteins
11/28/2001	EP1157043A1 Anti-gpr-9-6 and anti-teck antibodies and methods of identifying modulators of gpr-9-6 and teck functions
11/28/2001	EP1157040A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
11/28/2001	EP1157028A1 Novel substituted 11.beta steroid derivatives, method for preparing same and intermediates of said method, use as medicine and compositions containing them
11/28/2001	EP1157024A1 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors
11/28/2001	EP1157022A1 Pyridine compounds and their pharmaceutical use
11/28/2001	EP1157021A1 Sulfamato hydroxamic acid metalloprotease inhibitor
11/28/2001	EP1157003A1 Acylated aminoacetonitriles as cysteine protease inhibitors
11/28/2001	EP1157001A1 Oxamic acids and derivatives as thyroid receptor ligands
11/28/2001	EP1156999A1 Method for the preparation of a chiral-beta-amino ester
11/28/2001	EP1156855A1 Composition comprising a tramadol material and a selective cox-2 inhibitor drug
11/28/2001	EP1156810A2 Solution for injection for the treatment of arthroses
11/28/2001	EP1156794A1 Methods and compositions for the treatment of neuropathic pain, tinnitus, and other disorders using r(-)-ketoprofen
11/28/2001	EP0804469B1 T-cell affecting peptides
11/28/2001	CN1324403A PRV-1 gene and the use thereof
11/28/2001	CN1324353A Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same

1 ... 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 ... 820